Activation of Glutathione Peroxidase 4 as a Novel Anti-inflammatory Strategy

Cong Li, Xiaobing Deng, Xiaowen Xie, Ying Liu, José Pedro Friedmann Angeli, Luhua LaiFrontiers in Pharmacology 2018 · DOI

Abstract

The anti-oxidative enzyme, glutathione peroxidase 4 (GPX4), helps to promote inflammation resolution by eliminating oxidative species produced by the arachidonic acid (AA) metabolic network. Up-regulating its activity has been proposed as a promising strategy for inflammation intervention. In the present study, we aimed to study the effect of GPX4 activator on the AA metabolic network and inflammation related pathways. Using combined computational and experimental screen, we identified a novel compound that can activate the enzyme activity of GPX4 by more than two folds. We further assessed its potential in a series of cellular assays where GPX4 was demonstrated to play a regulatory role. We are able to show that GPX4 activation suppressed inflammatory conditions such as oxidation of AA and NF-κB pathway activation. We further demonstrated that this GPX4 activator can decrease the intracellular ROS level and suppress ferroptosis. Our study suggests that GPX4 activators can be developed as anti-inflammatory or cyto-protective agent in lipid-peroxidation-mediated diseases.

Introduction

Conventional anti-inflammatory strategies typically focus on the inhibition of key enzymes such as cyclooxygenase-2 (COX-2) or 5-lipoxygenase (5-LOX) to prevent the synthesis of pro-inflammatory mediators. However, this approach can lead to the accumulation of upstream precursors, potentially causing "shunting" into alternative inflammatory pathways or other adverse side effects.

This research explores an alternative paradigm: the activation of endogenous resolution pathways. Glutathione peroxidase 4 (GPX4) is a unique antioxidant enzyme that neutralizes lipid hydroperoxides, which are critical intermediates in the arachidonic acid (AA) metabolic network and primary drivers of ferroptosis (iron-dependent cell death). By enhancing GPX4 activity, it is possible to accelerate the clearance of these volatile "sparks" of inflammation.

GPX4 plays a central regulatory role in the arachidonic acid metabolic network by converting hydroperoxides (HpETEs) into less harmful hydroxides (HETEs).

Methods

The study utilized a rational drug design workflow integrating computational modeling with experimental validation. The authors identified a potential allosteric pocket on the GPX4 structure (PDB: 2OBI) using the CAVITY and CorrSite programs. A library of 197,276 small molecules from the SPECS database was virtually screened against this site.

Top-scoring candidates were evaluated in cell-free enzyme assays. The lead compound, PKUMDL-LC-102 (102), was further validated using site-directed mutagenesis (D23A mutant) and Cellular Thermal Shift Assays (CETSA) to confirm its physical interaction with the target protein in a cellular environment. Finally, LC-MS/MS was employed to track changes in the eicosanoid profile of human polymorphonuclear leukocytes (PMNs), while cellular assays assessed effects on ROS levels, NF-κB signaling, and ferroptosis in HEK293T and HT-1080 cell lines.

Results

The primary finding was the identification of compound 102 as a potent GPX4 activator.

  • Enzymatic Activation: Compound 102 demonstrated dose-dependent activation of GPX4, increasing its activity by up to 236%.
  • Oxidative Stress and Signaling: The activator reduced intracellular ROS levels (EC50 = 11.4 µM) and inhibited TNFα-induced NF-κB activation (EC50 = 60.8 µM), a master regulator of inflammatory gene expression.
  • Cytoprotection: In HT-1080 cells, compound 102 effectively prevented ferroptosis induced by erastin and RSL3, suggesting a robust protective effect against lipid membrane damage.
Dose-response curve showing the activation of hGPX4-C by compound 102, reaching over 200% activity.

Discussion

By targeting an allosteric site involving residue D23, the researchers successfully enhanced GPX4 function without interfering with the catalytic active site. This "back door" approach allows GPX4 to act as a metabolic "drain," clearing hydroperoxides (HpETEs) and shifting the AA network balance toward less inflammatory metabolites, thereby reducing the production of potent triggers like Leukotriene B4 (LTB4).

While compound 102 shows significant promise, its weak inhibition of the Hv1 proton channel suggests a need for further optimization to improve specificity. Future work should focus on medicinal chemistry to enhance potency and solubility, as well as demonstrating efficacy in in vivo animal models of inflammatory diseases. This study establishes GPX4 activation as a viable and innovative strategy for treating lipid-peroxidation-mediated inflammatory conditions.

Summary updated

Abstract

The anti-oxidative enzyme, glutathione peroxidase 4 (GPX4), helps to promote inflammation resolution by eliminating oxidative species produced by the arachidonic acid (AA) metabolic network. Up-regulating its activity has been proposed as a promising strategy for inflammation intervention. In the present study, we aimed to study the effect of GPX4 activator on the AA metabolic network and inflammation related pathways. Using combined computational and experimental screen, we identified a novel compound that can activate the enzyme activity of GPX4 by more than two folds. We further assessed its potential in a series of cellular assays where GPX4 was demonstrated to play a regulatory role. We are able to show that GPX4 activation suppressed inflammatory conditions such as oxidation of AA and NF-κB pathway activation. We further demonstrated that this GPX4 activator can decrease the intracellular ROS level and suppress ferroptosis. Our study suggests that GPX4 activators can be developed as anti-inflammatory or cyto-protective agent in lipid-peroxidation-mediated diseases.
BibTeX
@inproceedings{li2018activation,
  author = {Cong Li and Xiaobing Deng and Xiaowen Xie and Ying Liu and José Pedro Friedmann Angeli and Luhua Lai},
  title = {{Activation of Glutathione Peroxidase 4 as a Novel Anti-inflammatory Strategy}},
  booktitle = {Frontiers in Pharmacology},
  year = {2018},
  doi = {10.3389/fphar.2018.01120},
}
Figure